# Dassault Systemes BIOVIA

European software arms of global conglomerates (like Dassault Systemes BIOVIA) provide the deeply validated, rigidly structured LIMS required by legacy Big Pharma manufacturing sites.

Source: https://en.bioecon.ru/companies/biovia/
Updated: 2026-06-24

- Country: France

## Verifiable facts

| Fact | Value | Source |
| --- | --- | --- |
| Funding | Dassault Systèmes does not report specific funding rounds for the BIOVIA brand as it is an operating brand of the publicly traded company Dassault Systèmes. | https://investor.3ds.com/static-files/dc4d4da1-59c3-45cf-86db-7488e2fd0119, https://investor.3ds.com/static-files/f345f4ee-bb0a-489e-8c1d-f43f18f47506, https://www.3ds.com/newsroom/press-releases/dassault-systemes-solid-q2-results-and-confirming-full-year-objectives-delivering-ai-native-solutions-and-expanding-life-sciences-acquisition-arisglobal, https://www.itnewsonline.com/GlobeNewswire/Dassault-Systmes-reports-first-quarter-2026-results-in-line-with-objectives-and-confirms-full-year-outlook/120503 |
| Headquarters | San Diego, California, USA | https://www.3ds.com/assets/invest/2025-04/biovia-quality-statement.pdf |
| Certification | ISO 9001:2015 (3DEXPERIENCE platform cloud apps), ISO/IEC 27001:2013 (ScienceCloud) | https://blog.3ds.com/brands/biovia/gxp-compliance-in-the-cloud/, https://discover.3ds.com/biovia-unified-scientific-innovation, https://intuitionlabs.ai/articles/qumas-edms-life-sciences-guide, https://www.3ds.com/assets/invest/2025-04/biovia-quality-statement.pdf, https://www.3ds.com/products/biovia/regulatory-management |
| Regulatory approval | Products designed for FDA 21 CFR Part 11, GxP, and Annex 11 compliance. | https://blog.3ds.com/brands/biovia/gxp-compliance-in-the-cloud/, https://discover.3ds.com/biovia-unified-scientific-innovation, https://intuitionlabs.ai/articles/qumas-edms-life-sciences-guide, https://www.3ds.com/assets/invest/2025-04/biovia-quality-statement.pdf |
| Headcount | Dassault Systèmes total headcount is 25,967 as of December 31, 2025. Individual BIOVIA headcount is not disclosed separately. [medium confidence] | https://investor.3ds.com/news-releases/news-release-details/dassault-systemes-q2-well-aligned-objectives-reaffirming-2025, https://investor.3ds.com/news-releases/news-release-details/dassault-systemes-q4-revenue-growth-1-solid-operating-margin-and, https://investor.3ds.com/news-releases/news-release-details/dassault-systemes-solid-start-year-strong-subscription-growth, https://investor.3ds.com/static-files/f345f4ee-bb0a-489e-8c1d-f43f18f47506, https://www.appsruntheworld.com/customers-database/products/view/dassault-biovia |
| Revenue | Life Sciences software revenue (includes MEDIDATA and BIOVIA) was €1.08 billion for the full year 2025. BIOVIA revenue is not disclosed separately. | https://investor.3ds.com/news-releases/news-release-details/dassault-systemes-q2-well-aligned-objectives-reaffirming-2025, https://investor.3ds.com/news-releases/news-release-details/dassault-systemes-q4-revenue-growth-1-solid-operating-margin-and, https://investor.3ds.com/static-files/f345f4ee-bb0a-489e-8c1d-f43f18f47506, https://live.euronext.com/sites/default/files/esg_document_files/2026-06/064315_3DS_CORPORATE%20REPORT_2025_1_2026-06-17_10%3A46.pdf |

Independent sources: 3ds.com, appsruntheworld.com, blog.3ds.com, discover.3ds.com, intuitionlabs.ai, investor.3ds.com, itnewsonline.com, live.euronext.com

## Technologies

- [Laboratory execution systems (LES)](https://en.bioecon.ru/technology/laboratory-execution-systems/)
- [LIMS/ELN for bioproduction](https://en.bioecon.ru/technology/lims-eln-bioproduction/)